Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023
31 Enero 2024 - 6:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for indications in virology and immunology, today announced that it
plans to report its financial results for its fiscal first quarter
ended December 31, 2023 after the U.S. market closes on February 7,
2024. Enanta management will host a conference call at 4:30 p.m. ET
to discuss these results and provide an update on the company’s
business and research and development pipeline.
A live webcast of the event will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of
Enanta’s website at www.enanta.com. To join by phone, participants
can register for the call here. It is recommended that participants
register one day in advance or at a minimum of 30 minutes before
the call. Once registered, participants will receive an email with
the dial-in information. A replay of the webcast will be available
following the presentation and will be archived for at least 30
days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs with an emphasis on indications
in virology and immunology. Enanta’s research and development
programs are currently focused on respiratory syncytial virus and
chronic spontaneous urticaria and the company has previously
advanced clinical-stage compounds for SARS-CoV-2 and chronic
hepatitis B virus infection.
Glecaprevir, a protease inhibitor discovered by Enanta, is part
of one of the leading treatment regimens for curing chronic
hepatitis c virus (HCV) infection and is sold by AbbVie in numerous
countries under the tradenames MAVYRET® (U.S.) and MAVIRET®
(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s
royalties from HCV products developed under its collaboration with
AbbVie contribute ongoing funding to Enanta’s operations. Please
visit http://www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240131192600/en/
Media and Investors Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024